Loading…
Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells
Breast cancer stem cells (CSCs) are responsible for the initiation, recurrence, and metastasis of breast cancer. Sufficient evidence has established that breast cancer cells can spontaneously turn into breast CSCs. Thus, it is essential to simultaneously target breast CSCs and cancer cells to maximi...
Saved in:
| Published in: | International journal of nanomedicine 2017-01, Vol.12, p.6909-6921 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c435t-b88a86e105a70f6402f788244b125f770bd96e959c5f39e6cc168a85584361eb3 |
|---|---|
| cites | |
| container_end_page | 6921 |
| container_issue | |
| container_start_page | 6909 |
| container_title | International journal of nanomedicine |
| container_volume | 12 |
| creator | Li, Jun Xu, Wenqing Yuan, Xiaoli Chen, Huaiwen Song, Hao Wang, Bingquan Han, Jun |
| description | Breast cancer stem cells (CSCs) are responsible for the initiation, recurrence, and metastasis of breast cancer. Sufficient evidence has established that breast cancer cells can spontaneously turn into breast CSCs. Thus, it is essential to simultaneously target breast CSCs and cancer cells to maximize the efficacy of breast cancer therapy. HER2 has been found to be overexpressed in both breast CSCs and cancer cells. We developed salinomycin-loaded polymer-lipid hybrid anti-HER2 nanoparticles (Sali-NP-HER2) to target both HER2-positive breast CSCs and cancer cells.
The antitumor activity of Sali-NP-HER2 constructed by conjugating anti-HER2 antibodies to polymer-lipid salinomycin nanoparticles was evaluated in vitro and in vivo.
Sali-NP-HER2 efficiently bound to HER2-positive breast CSCs and cancer cells, resulting in enhanced cytotoxic effects compared with non-targeted nanoparticles or salinomycin. In mice bearing breast cancer xenografts, administration of Sali-NP-HER2 exhibited superior efficacy in inhibiting tumor growth. Sali-NP-HER2 reduced the breast tumorsphere formation rate and the proportion of breast CSCs more effectively than non-targeted nanoparticles or salinomycin alone.
Sali-NP-HER2 represents a promising approach in treating HER2-positive breast cancer by targeting both breast CSCs and cancer cells. |
| doi_str_mv | 10.2147/IJN.S144184 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_ee288ab9e1644ebf9210f26d70a1942d</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A532303269</galeid><doaj_id>oai_doaj_org_article_ee288ab9e1644ebf9210f26d70a1942d</doaj_id><sourcerecordid>A532303269</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-b88a86e105a70f6402f788244b125f770bd96e959c5f39e6cc168a85584361eb3</originalsourceid><addsrcrecordid>eNptUl1rFDEUHUSxtfrkuwR8lFmTTD4mL0Ip1a4UFT-eQyZzs80yk6zJbGF-gv_abHdbuyB5uOHcc869F05VvSZ4QQmT75efvyx-EMZIy55Up4TItqaYNE8f_U-qFzmvMeayFep5dUIVlpwQfFr9-RaHeYRUD37je3Qzd6kUEyZfX11-pyiYEDcmTd4OkJGLCU0mrWCCHmUz-BDH2fqAehj8LaQZTRHtdPUmZj8VCHUJTJ6QNcFCQnmCEVkYhlxm9PfoHfCyeubMkOHVoZ5Vvz5e_ry4qq-_flpenF_XljV8qru2Na0AgrmR2AmGqZNtSxnrCOVOStz1SoDiynLXKBDWElEUnLesEQS65qxa7n37aNZ6k_xo0qyj8foOiGmlD_dqAFqmdQqIYAw6pyjBjopeYkMUo33x-rD32my7EXoLYUpmODI97gR_o1fxVnOBlWybYvD2YJDi7y3kSa_jNoVyv6a0UbuBXP5jrUzZygcXi5kdfbb6nDe0wQ0VqrAW_2GV18PobQzgfMGPBO_2Aptizgncw-IE6120dImWPkSrsN88vvWBe5-l5i9StckM</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2239921057</pqid></control><display><type>article</type><title>Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><source>Taylor & Francis Open Access Journals</source><creator>Li, Jun ; Xu, Wenqing ; Yuan, Xiaoli ; Chen, Huaiwen ; Song, Hao ; Wang, Bingquan ; Han, Jun</creator><creatorcontrib>Li, Jun ; Xu, Wenqing ; Yuan, Xiaoli ; Chen, Huaiwen ; Song, Hao ; Wang, Bingquan ; Han, Jun</creatorcontrib><description>Breast cancer stem cells (CSCs) are responsible for the initiation, recurrence, and metastasis of breast cancer. Sufficient evidence has established that breast cancer cells can spontaneously turn into breast CSCs. Thus, it is essential to simultaneously target breast CSCs and cancer cells to maximize the efficacy of breast cancer therapy. HER2 has been found to be overexpressed in both breast CSCs and cancer cells. We developed salinomycin-loaded polymer-lipid hybrid anti-HER2 nanoparticles (Sali-NP-HER2) to target both HER2-positive breast CSCs and cancer cells.
The antitumor activity of Sali-NP-HER2 constructed by conjugating anti-HER2 antibodies to polymer-lipid salinomycin nanoparticles was evaluated in vitro and in vivo.
Sali-NP-HER2 efficiently bound to HER2-positive breast CSCs and cancer cells, resulting in enhanced cytotoxic effects compared with non-targeted nanoparticles or salinomycin. In mice bearing breast cancer xenografts, administration of Sali-NP-HER2 exhibited superior efficacy in inhibiting tumor growth. Sali-NP-HER2 reduced the breast tumorsphere formation rate and the proportion of breast CSCs more effectively than non-targeted nanoparticles or salinomycin alone.
Sali-NP-HER2 represents a promising approach in treating HER2-positive breast cancer by targeting both breast CSCs and cancer cells.</description><identifier>ISSN: 1178-2013</identifier><identifier>ISSN: 1176-9114</identifier><identifier>EISSN: 1178-2013</identifier><identifier>DOI: 10.2147/IJN.S144184</identifier><identifier>PMID: 29075110</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Animals ; Antibodies ; Antibodies, Monoclonal - chemistry ; Antibodies, Monoclonal - pharmacology ; Aqueous solutions ; Biocompatibility ; Biomedical materials ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Cancer cells ; Cancer metastasis ; Cancer stem cells ; Cancer therapies ; Cell Line, Tumor ; Cytotoxicity ; Dehydrogenases ; Drug delivery systems ; Drug Delivery Systems - methods ; Female ; Health aspects ; HER2 ; Humans ; Lipids ; Lipids - chemistry ; Liver cancer ; Metastasis ; Mice ; Nanoparticles ; Nanoparticles - administration & dosage ; Nanoparticles - chemistry ; Neoplastic Stem Cells - drug effects ; Neoplastic Stem Cells - pathology ; Original Research ; Polyethylene glycol ; Polymers ; Polymers - chemistry ; Pyrans - administration & dosage ; Receptor, ErbB-2 - antagonists & inhibitors ; Receptor, ErbB-2 - immunology ; Receptor, ErbB-2 - metabolism ; Salinomycin ; Stem cells ; Tumorigenesis ; Xenograft Model Antitumor Assays</subject><ispartof>International journal of nanomedicine, 2017-01, Vol.12, p.6909-6921</ispartof><rights>COPYRIGHT 2017 Dove Medical Press Limited</rights><rights>2017. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2017 Li et al. This work is published and licensed by Dove Medical Press Limited 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-b88a86e105a70f6402f788244b125f770bd96e959c5f39e6cc168a85584361eb3</citedby><orcidid>0000-0003-0516-5894</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2239921057/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2239921057?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25732,27903,27904,36991,44569,53769,53771,74872</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29075110$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Jun</creatorcontrib><creatorcontrib>Xu, Wenqing</creatorcontrib><creatorcontrib>Yuan, Xiaoli</creatorcontrib><creatorcontrib>Chen, Huaiwen</creatorcontrib><creatorcontrib>Song, Hao</creatorcontrib><creatorcontrib>Wang, Bingquan</creatorcontrib><creatorcontrib>Han, Jun</creatorcontrib><title>Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells</title><title>International journal of nanomedicine</title><addtitle>Int J Nanomedicine</addtitle><description>Breast cancer stem cells (CSCs) are responsible for the initiation, recurrence, and metastasis of breast cancer. Sufficient evidence has established that breast cancer cells can spontaneously turn into breast CSCs. Thus, it is essential to simultaneously target breast CSCs and cancer cells to maximize the efficacy of breast cancer therapy. HER2 has been found to be overexpressed in both breast CSCs and cancer cells. We developed salinomycin-loaded polymer-lipid hybrid anti-HER2 nanoparticles (Sali-NP-HER2) to target both HER2-positive breast CSCs and cancer cells.
The antitumor activity of Sali-NP-HER2 constructed by conjugating anti-HER2 antibodies to polymer-lipid salinomycin nanoparticles was evaluated in vitro and in vivo.
Sali-NP-HER2 efficiently bound to HER2-positive breast CSCs and cancer cells, resulting in enhanced cytotoxic effects compared with non-targeted nanoparticles or salinomycin. In mice bearing breast cancer xenografts, administration of Sali-NP-HER2 exhibited superior efficacy in inhibiting tumor growth. Sali-NP-HER2 reduced the breast tumorsphere formation rate and the proportion of breast CSCs more effectively than non-targeted nanoparticles or salinomycin alone.
Sali-NP-HER2 represents a promising approach in treating HER2-positive breast cancer by targeting both breast CSCs and cancer cells.</description><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies, Monoclonal - chemistry</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Aqueous solutions</subject><subject>Biocompatibility</subject><subject>Biomedical materials</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer cells</subject><subject>Cancer metastasis</subject><subject>Cancer stem cells</subject><subject>Cancer therapies</subject><subject>Cell Line, Tumor</subject><subject>Cytotoxicity</subject><subject>Dehydrogenases</subject><subject>Drug delivery systems</subject><subject>Drug Delivery Systems - methods</subject><subject>Female</subject><subject>Health aspects</subject><subject>HER2</subject><subject>Humans</subject><subject>Lipids</subject><subject>Lipids - chemistry</subject><subject>Liver cancer</subject><subject>Metastasis</subject><subject>Mice</subject><subject>Nanoparticles</subject><subject>Nanoparticles - administration & dosage</subject><subject>Nanoparticles - chemistry</subject><subject>Neoplastic Stem Cells - drug effects</subject><subject>Neoplastic Stem Cells - pathology</subject><subject>Original Research</subject><subject>Polyethylene glycol</subject><subject>Polymers</subject><subject>Polymers - chemistry</subject><subject>Pyrans - administration & dosage</subject><subject>Receptor, ErbB-2 - antagonists & inhibitors</subject><subject>Receptor, ErbB-2 - immunology</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Salinomycin</subject><subject>Stem cells</subject><subject>Tumorigenesis</subject><subject>Xenograft Model Antitumor Assays</subject><issn>1178-2013</issn><issn>1176-9114</issn><issn>1178-2013</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptUl1rFDEUHUSxtfrkuwR8lFmTTD4mL0Ip1a4UFT-eQyZzs80yk6zJbGF-gv_abHdbuyB5uOHcc869F05VvSZ4QQmT75efvyx-EMZIy55Up4TItqaYNE8f_U-qFzmvMeayFep5dUIVlpwQfFr9-RaHeYRUD37je3Qzd6kUEyZfX11-pyiYEDcmTd4OkJGLCU0mrWCCHmUz-BDH2fqAehj8LaQZTRHtdPUmZj8VCHUJTJ6QNcFCQnmCEVkYhlxm9PfoHfCyeubMkOHVoZ5Vvz5e_ry4qq-_flpenF_XljV8qru2Na0AgrmR2AmGqZNtSxnrCOVOStz1SoDiynLXKBDWElEUnLesEQS65qxa7n37aNZ6k_xo0qyj8foOiGmlD_dqAFqmdQqIYAw6pyjBjopeYkMUo33x-rD32my7EXoLYUpmODI97gR_o1fxVnOBlWybYvD2YJDi7y3kSa_jNoVyv6a0UbuBXP5jrUzZygcXi5kdfbb6nDe0wQ0VqrAW_2GV18PobQzgfMGPBO_2Aptizgncw-IE6120dImWPkSrsN88vvWBe5-l5i9StckM</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Li, Jun</creator><creator>Xu, Wenqing</creator><creator>Yuan, Xiaoli</creator><creator>Chen, Huaiwen</creator><creator>Song, Hao</creator><creator>Wang, Bingquan</creator><creator>Han, Jun</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove Medical Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0516-5894</orcidid></search><sort><creationdate>20170101</creationdate><title>Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells</title><author>Li, Jun ; Xu, Wenqing ; Yuan, Xiaoli ; Chen, Huaiwen ; Song, Hao ; Wang, Bingquan ; Han, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-b88a86e105a70f6402f788244b125f770bd96e959c5f39e6cc168a85584361eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies, Monoclonal - chemistry</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Aqueous solutions</topic><topic>Biocompatibility</topic><topic>Biomedical materials</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer cells</topic><topic>Cancer metastasis</topic><topic>Cancer stem cells</topic><topic>Cancer therapies</topic><topic>Cell Line, Tumor</topic><topic>Cytotoxicity</topic><topic>Dehydrogenases</topic><topic>Drug delivery systems</topic><topic>Drug Delivery Systems - methods</topic><topic>Female</topic><topic>Health aspects</topic><topic>HER2</topic><topic>Humans</topic><topic>Lipids</topic><topic>Lipids - chemistry</topic><topic>Liver cancer</topic><topic>Metastasis</topic><topic>Mice</topic><topic>Nanoparticles</topic><topic>Nanoparticles - administration & dosage</topic><topic>Nanoparticles - chemistry</topic><topic>Neoplastic Stem Cells - drug effects</topic><topic>Neoplastic Stem Cells - pathology</topic><topic>Original Research</topic><topic>Polyethylene glycol</topic><topic>Polymers</topic><topic>Polymers - chemistry</topic><topic>Pyrans - administration & dosage</topic><topic>Receptor, ErbB-2 - antagonists & inhibitors</topic><topic>Receptor, ErbB-2 - immunology</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Salinomycin</topic><topic>Stem cells</topic><topic>Tumorigenesis</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Jun</creatorcontrib><creatorcontrib>Xu, Wenqing</creatorcontrib><creatorcontrib>Yuan, Xiaoli</creatorcontrib><creatorcontrib>Chen, Huaiwen</creatorcontrib><creatorcontrib>Song, Hao</creatorcontrib><creatorcontrib>Wang, Bingquan</creatorcontrib><creatorcontrib>Han, Jun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of nanomedicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Jun</au><au>Xu, Wenqing</au><au>Yuan, Xiaoli</au><au>Chen, Huaiwen</au><au>Song, Hao</au><au>Wang, Bingquan</au><au>Han, Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells</atitle><jtitle>International journal of nanomedicine</jtitle><addtitle>Int J Nanomedicine</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>12</volume><spage>6909</spage><epage>6921</epage><pages>6909-6921</pages><issn>1178-2013</issn><issn>1176-9114</issn><eissn>1178-2013</eissn><abstract>Breast cancer stem cells (CSCs) are responsible for the initiation, recurrence, and metastasis of breast cancer. Sufficient evidence has established that breast cancer cells can spontaneously turn into breast CSCs. Thus, it is essential to simultaneously target breast CSCs and cancer cells to maximize the efficacy of breast cancer therapy. HER2 has been found to be overexpressed in both breast CSCs and cancer cells. We developed salinomycin-loaded polymer-lipid hybrid anti-HER2 nanoparticles (Sali-NP-HER2) to target both HER2-positive breast CSCs and cancer cells.
The antitumor activity of Sali-NP-HER2 constructed by conjugating anti-HER2 antibodies to polymer-lipid salinomycin nanoparticles was evaluated in vitro and in vivo.
Sali-NP-HER2 efficiently bound to HER2-positive breast CSCs and cancer cells, resulting in enhanced cytotoxic effects compared with non-targeted nanoparticles or salinomycin. In mice bearing breast cancer xenografts, administration of Sali-NP-HER2 exhibited superior efficacy in inhibiting tumor growth. Sali-NP-HER2 reduced the breast tumorsphere formation rate and the proportion of breast CSCs more effectively than non-targeted nanoparticles or salinomycin alone.
Sali-NP-HER2 represents a promising approach in treating HER2-positive breast cancer by targeting both breast CSCs and cancer cells.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>29075110</pmid><doi>10.2147/IJN.S144184</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-0516-5894</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1178-2013 |
| ispartof | International journal of nanomedicine, 2017-01, Vol.12, p.6909-6921 |
| issn | 1178-2013 1176-9114 1178-2013 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_ee288ab9e1644ebf9210f26d70a1942d |
| source | Open Access: PubMed Central; Publicly Available Content Database; Taylor & Francis Open Access Journals |
| subjects | Animals Antibodies Antibodies, Monoclonal - chemistry Antibodies, Monoclonal - pharmacology Aqueous solutions Biocompatibility Biomedical materials Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer cells Cancer metastasis Cancer stem cells Cancer therapies Cell Line, Tumor Cytotoxicity Dehydrogenases Drug delivery systems Drug Delivery Systems - methods Female Health aspects HER2 Humans Lipids Lipids - chemistry Liver cancer Metastasis Mice Nanoparticles Nanoparticles - administration & dosage Nanoparticles - chemistry Neoplastic Stem Cells - drug effects Neoplastic Stem Cells - pathology Original Research Polyethylene glycol Polymers Polymers - chemistry Pyrans - administration & dosage Receptor, ErbB-2 - antagonists & inhibitors Receptor, ErbB-2 - immunology Receptor, ErbB-2 - metabolism Salinomycin Stem cells Tumorigenesis Xenograft Model Antitumor Assays |
| title | Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T02%3A22%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Polymer-lipid%20hybrid%20anti-HER2%20nanoparticles%20for%20targeted%20salinomycin%20delivery%20to%20HER2-positive%20breast%20cancer%20stem%20cells%20and%20cancer%20cells&rft.jtitle=International%20journal%20of%20nanomedicine&rft.au=Li,%20Jun&rft.date=2017-01-01&rft.volume=12&rft.spage=6909&rft.epage=6921&rft.pages=6909-6921&rft.issn=1178-2013&rft.eissn=1178-2013&rft_id=info:doi/10.2147/IJN.S144184&rft_dat=%3Cgale_doaj_%3EA532303269%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c435t-b88a86e105a70f6402f788244b125f770bd96e959c5f39e6cc168a85584361eb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2239921057&rft_id=info:pmid/29075110&rft_galeid=A532303269&rfr_iscdi=true |